BRIEF-Cytokinetics expects results from VITALITY-ALS in 2H 2017 By: Reuters: Company News August 17, 2016 at 07:54 AM EDT * Cytokinetics completes enrollment in VITALITY-ALS, phase 3 clinical trial of Tirasemtiv in patients with ALS Read More >> Related Stocks: Cytokinetics